NAS
LEGN icon

Nykredit A/S’s Legend Biotech LEGN Stock Holding History

Nykredit A/S’s Portfolio LEGN Stock Details LEGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$162K Buy
+5,614
New +$151K ﹤0.01% 1124

Other funds holding LEGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
DCP
Davern Capital Partners Ny, New York $587M AUM
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Nykredit A/S's LEGN Position: Q2 2026 in Review

Nykredit A/S opened a new position in Legend Biotech (LEGN) in Q2 2026: 5,614 shares worth $162K. The stake represents ﹤0.01% of the portfolio and ranks #1124 among its holdings.

151 funds tracked by Wall St. Rank hold LEGN as of Q2 2026.

  • Nykredit A/S held 5,614 shares of Legend Biotech worth $162K as of Q2 2026.
  • Legend Biotech was a new Nykredit A/S position in Q2 2026.
  • Legend Biotech made up ﹤0.01% of Nykredit A/S's portfolio in Q2 2026, its #1124 holding.
  • 151 funds tracked by Wall St. Rank held Legend Biotech as of Q2 2026.

Based on Nykredit A/S's 13F filing for Q2 2026, filed 13 Aug 2026.